Research Analysts Offer Predictions for 908 Devices Inc.’s Q1 2025 Earnings (NASDAQ:MASS)

908 Devices Inc. (NASDAQ:MASS) – Equities researchers at William Blair issued their Q1 2025 earnings per share (EPS) estimates for 908 Devices in a report issued on Tuesday, April 30th. William Blair analyst M. Larew forecasts that the company will post earnings per share of ($0.35) for the quarter. The consensus estimate for 908 Devices’ current full-year earnings is ($1.27) per share. William Blair also issued estimates for 908 Devices’ Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.23) EPS and Q4 2025 earnings at ($0.19) EPS.

908 Devices Price Performance

MASS stock opened at $5.68 on Thursday. 908 Devices has a fifty-two week low of $4.85 and a fifty-two week high of $12.51. The business’s 50-day moving average is $6.59 and its two-hundred day moving average is $7.08.

908 Devices (NASDAQ:MASS) last released its quarterly earnings data on Tuesday, April 30th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.03. 908 Devices had a negative return on equity of 20.47% and a negative net margin of 68.57%. The company had revenue of $9.99 million for the quarter, compared to analysts’ expectations of $9.29 million. During the same period last year, the firm posted ($0.39) earnings per share. 908 Devices’s revenue was up 5.3% compared to the same quarter last year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of MASS. Bank of New York Mellon Corp raised its stake in shares of 908 Devices by 11.1% in the third quarter. Bank of New York Mellon Corp now owns 93,775 shares of the company’s stock worth $625,000 after buying an additional 9,393 shares during the period. Sumitomo Mitsui Trust Holdings Inc. raised its stake in shares of 908 Devices by 3.0% in the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 629,994 shares of the company’s stock worth $4,196,000 after buying an additional 18,492 shares during the period. Arete Wealth Advisors LLC raised its stake in shares of 908 Devices by 35.8% in the third quarter. Arete Wealth Advisors LLC now owns 22,758 shares of the company’s stock worth $152,000 after buying an additional 5,997 shares during the period. New York State Common Retirement Fund raised its stake in shares of 908 Devices by 15.3% in the third quarter. New York State Common Retirement Fund now owns 70,525 shares of the company’s stock worth $470,000 after buying an additional 9,346 shares during the period. Finally, Values First Advisors Inc. raised its stake in shares of 908 Devices by 24.5% in the third quarter. Values First Advisors Inc. now owns 16,726 shares of the company’s stock worth $111,000 after buying an additional 3,294 shares during the period. Institutional investors own 88.06% of the company’s stock.

908 Devices Company Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.